Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by
distortion of the hepatic architecture and formation of regenerative nodules. The liver
transplantation is one of the only effective therapies available to such patients. However,
lack of donors, surgical complications, rejection, and high cost are it's serious problems.
The potential for stem cells to differentiate into hepatocytes cells was recently confirmed.
Particularly, autologous bone marrow-derived mesenchymal stem cell (BM-MSC) has been
demonstrated to decrease MELD score and increase serum albumin in the patients with
decompensated liver cirrhosis. Therefore, the investigators propose a hypothesis that
umbilical cord-derived MSCs (UC-MSC) can also improve the disease conditions of LC patients,
particularly reducing the decompensated conditions in these patients.